Full Press Release Details
Enlivex Appoints Dr. Roger J. Pomerantz to its
Board of Directors as Vice Chairman
Nes-Ziona, Israel, May 23, 2022 (GLOBE NEWSWIRE) - Enlivex
Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced
the appointment of Roger J. Pomerantz, M.D., FACP, to its Board of Directors as Vice Chairman. Dr. Pomerantz is a pharmaceutical and biotech
industry veteran who has led scientific, drug and business development functions throughout his stellar career.
Dr. Pomerantz has held notable positions in both large pharma and small
biotech companies. He served as Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led
the completion of more than 150 business development transactions, and as Global Head of Infectious Diseases for Johnson & Johnson
Pharmaceuticals. Following his tenure with large pharma, Dr. Pomerantz joined Flagship Pioneering, which conceives, creates, and develops
bioplatform companies. Since its launch in 2000, Flagship has originated more than 100 scientific ventures such as Moderna, collectively
resulting in more than $140 billion in aggregate value. On behalf of Flagship, Dr. Pomerantz was appointed President, Chief Executive
Officer (CEO), and Chairman of the Board of Seres Therapeutics (Nasdaq: MCRB), a clinical stage biopharma company targeting the human
microbiome. While at Seres, he helped close a significant business development transaction with Nestle Health Sciences for a $150 million
up-front payment and a total transaction value of approximately $2 billion. Throughout his career, Dr. Pomerantz led the development of
13 drugs that have been approved and launched world-wide in a range of therapeutic areas. He is currently the President, CEO, and Chairman
of the Board of Directors of ContraFect Corporation (Nasdaq: CFRX), and serves as a Board member at several other biotech companies including
Viracta Therapeutics, Inc. (Nasdaq: VIRX), Indaptus Therapeutics Inc. (Nasdaq: INDP), Collplant Biotechnologies Ltd. (Nasdaq: CLGN), and
X-Vax Inc. Dr. Pomerantz received his B.A. in Biochemistry at Johns Hopkins University and his M.D. at the Johns Hopkins
School of Medicine. He received post-graduate training at Massachusetts General Hospital, Harvard Medical School, and Massachusetts
Institute of Technology. Dr. Pomerantz is board certified in both internal medicine and infectious diseases. Prior to his career in the
biotechnology industry, he was a tenured Professor of Medicine, Biochemistry, and Molecular Pharmacology, Chief of Infectious Diseases,
and the Founding Director and Chair of the Institute for Human Virology and Biodefense at Thomas Jefferson University and Medical
"It is an honor to join Enlivex as Vice Chairman of the Board
at this important juncture in the Company's evolution," said Dr. Pomerantz. "I have always been interested in the role
of macrophages across multiple diseases ever since I was an HIV researcher, and I am fascinated with the preclinical and clinical data
demonstrating the broad applicability of Allocetra's novel mechanism of action. These data highlight the potential of this next
generation cell therapy to serve patients with a range of diseases characterized by imbalances in macrophage homeostasis. I look forward
to collaborating with my fellow Board members and the Company's management team as we work to advance Allocetra's development
in sepsis and initiate its clinical program in solid tumors. With talented leadership, strong data, and expected cash runway into Q3 2024,
I believe Enlivex is well positioned for sustained success."
Shai Novik, Executive Chairman of the Board of Enlivex, stated, "Dr.
Pomerantz's business development acumen and track record of creating shareholder value by successfully developing drugs make him
an ideal fit for Enlivex's Board. We look forward to benefiting from his expert insights as we execute on our clinical and corporate
strategy. It is my pleasure to welcome him to the Company as the Vice Chairman."
Allocetra is being developed as a universal, off-the-shelf
cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, and many others reprogram
macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective
diseases. By restoring macrophage homeostasis, Allocetra has the potential to provide a novel immunotherapeutic mechanism
of action for life-threatening clinical indications that are defined as "unmet medical needs", as a stand-alone therapy or
in combination with leading therapeutic agents.
Enlivex is a clinical stage macrophage reprogramming
immunotherapy company developing Allocetra , a universal, off-the-shelf cell therapy designed to reprogram macrophages into
their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing
and resolution of life-threatening conditions. For more information, visit https://enlivex.com/.
Safe Harbor Statement: This press
release contains forward-looking statements, which may be identified by words such as "expects," "plans," "projects,"
"will," "may," "anticipates," "believes," "should," "would", "could,"
"intends," "estimates," "suggests," "has the potential to" and other words of similar
meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical
experiments, the effectiveness of, and market opportunities for, ALLOCETRATM programs. All such forward-looking statements
are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned
that forward-looking statements involve risks and uncertainties that may affect Enlivex's business and prospects, including
the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in
development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval
or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show
substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the
forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of
clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage
trials. The development of any products using the ALLOCETRATM product line could also be affected by a number of other
factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making,
the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary
rights held by competitors and other third parties. In addition to the risk factors described above, investors should consider the
economic, competitive, governmental, technological and other factors discussed in Enlivex's filings with the
Securities and Exchange Commission, including in the Company's most recent Annual Report on Form 20-F filed with the Securities
and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements
were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.
INVESTOR RELATIONS CONTACT